Dacarbazine — Class III drug recall D-0313-2015
Terminated recall by Hospira Inc., reported 2014-12-31, distributed nationwide. Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the
| Recall number | D-0313-2015 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Hospira Inc., Lake Forest, IL, United States |
| Recall initiated | 2014-11-25 |
| Classified | 2014-12-22 |
| Reported by FDA | 2014-12-31 |
| Terminated | 2016-12-15 |
| Distributed | Nationwide (US) |
| Quantity | 3,306 vials |
| Reason classes | labeling |
| NDC | 61703-0327-22 |
| Lot numbers | B032223AA |
| Expiration dates | 2016-07-20 |
Product
Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22.
Reason for recall
Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0313-2015. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.